Revvityは2025年第4四半期の収益と収益予測を上回り,2026年の予測を上げ,株価を上昇させた. Revvity beat earnings and revenue forecasts for Q4 2025 and raised 2026 guidance, boosting its stock.

Revvity Inc.は,予想以上に強い2025年第4四半期の業績を報告し,調整後の利益は1株当たり1.70ドル,収益は7億7200万ドルで,予測を上回った. Revvity Inc. reported stronger-than-expected fourth-quarter 2025 results, with adjusted earnings of $1.70 per share and revenue of $772 million, surpassing forecasts. 同社は2026年の予測を上げ,株当たり5.35ドルから5.45ドルと,分析家の見積もりよりも高い296億から299億ドルの収益を予測した. The company raised its 2026 guidance, projecting earnings of $5.35 to $5.45 per share and revenue of $2.96 billion to $2.99 billion, both above analyst estimates. 成長は,医薬品部門の効力によって支えられている診断及び生命科学の需要によって推し進められた. Growth was driven by demand in diagnostics and life sciences, supported by pharmaceutical sector strength. 株式は開示後に市場前取引で上昇した. The stock rose in pre-market trading following the announcement.